TYLOVET 25% premix for medicated feed for chickens, turkeys, calves for fattening 250 mg/g Bulgaria - Bulgarian - БАБХ (Българска агенция по безопасност на храните)

tylovet 25% premix for medicated feed for chickens, turkeys, calves for fattening 250 mg/g

Биовет АД - Тилозин (под формата на фосфат) - премикс за медикаментозен фураж - 250 mg/g - пилета, пуйки, телета

VETMULIN 100 g/kg premix for medicated feeding stuff for pigs, chickens, turkey and rabbies 100 g/kg Bulgaria - Bulgarian - БАБХ (Българска агенция по безопасност на храните)

vetmulin 100 g/kg premix for medicated feeding stuff for pigs, chickens, turkey and rabbies 100 g/kg

huvepharma nv - Тиамулина гидроген фумарат - премикс за медикаментозен фураж - 100 g/kg - зайци, кокошки, пуйки, свине

VETMULIN 20 g/kg premix for medicated feeding stuff for pigs, chickens, turkey and rabbits 20 mg/kg Bulgaria - Bulgarian - БАБХ (Българска агенция по безопасност на храните)

vetmulin 20 g/kg premix for medicated feeding stuff for pigs, chickens, turkey and rabbits 20 mg/kg

huvepharma nv - Тиамулина гидроген фумарат - премикс за медикаментозен фураж - 20 mg/kg - зайци, кокошки, пуйки, свине

ZINCOPREMIX 1000 mg/g premix for medicated feeding stuff for pigs 1000 mg/g Bulgaria - Bulgarian - БАБХ (Българска агенция по безопасност на храните)

zincopremix 1000 mg/g premix for medicated feeding stuff for pigs 1000 mg/g

andres pintaluba s.a. - Цинков Оксид - медикаментозен премикс - 1000 mg/g - прасета

ALPHADOXAN 100 mg/g Premix for Medicated Feeding Stuff for Pigs 100 mg/g Bulgaria - Bulgarian - БАБХ (Българска агенция по безопасност на храните)

alphadoxan 100 mg/g premix for medicated feeding stuff for pigs 100 mg/g

alpha-vet veterinary ltd. - Доксициклин - премикс за медикаментозен фураж - 100 mg/g - свине

ALPHAFLOROVET 20 mg/g Premix for Medicated Feeding Stuff for Pigs 20 mg/g Bulgaria - Bulgarian - БАБХ (Българска агенция по безопасност на храните)

alphaflorovet 20 mg/g premix for medicated feeding stuff for pigs 20 mg/g

alpha-vet veterinary ltd. - Флорфеникол - премикс за медикаментозен фураж - 20 mg/g - прасета

SomaKit TOC European Union - Bulgarian - EMA (European Medicines Agency)

somakit toc

advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - Диагностични радиофармацевтици - Този лекарствен продукт е само за диагностична употреба. След radiolabelling с галлием (68га) разтвор на хлорид, разтвор на галий (68га) edotreotide получени предназначени за позитронна-емисионна томография (pet) визуализация на рецепторите на соматостатин сверхэкспрессия при възрастни пациенти с потвърдена или предполагаема высокодифференцированных стомашно-enteropancreatic нейроэндокринные тумори (gap-net) за локализиране на първични тумори и техните метастази.

Axumin European Union - Bulgarian - EMA (European Medicines Agency)

axumin

blue earth diagnostics ireland ltd - fluciclovine (18f) - prostatic neoplasms; radionuclide imaging - Диагностични радиофармацевтици - Този лекарствен продукт е само за диагностична употреба. axumin е показан за позитронна-емисионна томография (pet) резонанс за откриване на рецидив на рак на простатната жлеза при възрастни мъже с подозрение на рецидив, на базата на високо кръвно нива простатического специфичния антиген (psa) след първоначалното лечение.

Opdivo European Union - Bulgarian - EMA (European Medicines Agency)

opdivo

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - Антинеопластични средства - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Spherox European Union - Bulgarian - EMA (European Medicines Agency)

spherox

co.don gmbh - сфероиди на хондроцити, свързани с човешка автоложна матрица - Хронични заболявания - Други лекарства за нарушения на мускулно-скелетната система - Ремонт на дефекти на симптоматична ставния хрущял на бедрената кондила и патела на коляното (Международната хрущял ремонт общество [icrs] клас iii или iv) с дефект размери до 10 cm2 при възрастни.